Publications | Lund University Publications

1 – 9 of 9

show: 10
|
sort: year (new to old)

News feed Embed this list Save this search Mark all Export

Cancel

Embed this list

copy and paste the html snippet below into your own page:

<iframe src="https://lup.lub.lu.se/search/publication?embed=1&q=keywords+exact+%22tolerability%22&amp;hide_pagination=1&amp;hide_info=1&amp;hide_options=1"
  width="100%"
  height="400"
  allowtransparency="true"
  frameborder="0">
</iframe>

2022
Mark The Effectiveness and Tolerability of a Very Low-Volume Bowel Preparation for Colonoscopy Compared to Low and High-Volume Polyethylene Glycol-Solutions in the Real-Life Setting
Bednarska, Olga ; Nyhlin, Nils ; Schmidt, Peter Thelin ; Johansson, Gabriele Wurm ^LU ; Toth, Ervin ^LU and Lindfors, Perjohan (2022) In Diagnostics 12(5).
- Contribution to journal › Article
2020
Mark Tolerability of non-ergot oral and transdermal dopamine agonists in younger and older Parkinson’s disease patients : an European multicentre survey
Rizos, A. ; Sauerbier, A. ; Falup-Pecurariu, C. ; Odin, P. ^LU ; Antonini, A. ; Martinez-Martin, P. ; Kessel, B. ; Henriksen, T. ; Silverdale, M. and Durner, G. , et al. (2020) In Journal of Neural Transmission 127(6). p.875-879
- Contribution to journal › Article
2019
Mark Tolerability of subcutaneous immunoglobulin 20%, Ig20Gly, in pediatric patients with primary immunodeficiencies
Paris, Kenneth ; Haddad, Elie ; Borte, Michael ; Brodszki, Nicholas ^LU ; Dérfalvi, Beáta ; Maródi, Laszlo ; Hussain, Iftikhar ; Darter, Amy ; Engl, Werner and Leibl, Heinz , et al. (2019) In Immunotherapy 11(5). p.397-406
- Contribution to journal › Article
2017
Mark Ponezumab in mild-to-moderate Alzheimer's disease : Randomized phase II PET-PIB study
Landen, Jaren W. ; Andreasen, Niels ; Cronenberger, Carol L. ; Schwartz, Pamela F. ; Börjesson-Hanson, Anne ; Östlund, Henrik ^LU ; Sattler, Catherine A. ; Binneman, Brendon and Bednar, Martin M. (2017) In Alzheimer's and Dementia: Translational Research and Clinical Interventions 3(3). p.393-401
- Contribution to journal › Article
2013
Mark Open-label parallel dose tolerability study of three subcutaneous immunotherapy regimens in house dust mite allergic patients
Rieker-Schwienbacher, Juliane ; Nell, Marja J ; Diamant, Zuzana ^LU ; van Ree, Ronald ; Distler, Andreas ; Boot, Johan D and Kleine-Tebbe, Jörg (2013) In Clinical and Translational Allergy 3(16).
- Contribution to journal › Article
2012
Mark Skin toxicity and quality of life in patients with metastatic colorectal cancer during first-line panitumumab plus FOLFIRI treatment in a single-arm phase II study
Thaler, Josef ; Karthaus, Meinolf ; Mineur, Laurent ; Greil, Richard ; Letocha, Henry ; Hofheinz, Ralf ; Fernebro, Eva ^LU ; Gamelin, Erick ; Banos, Ana and Koehne, Claus-Henning (2012) In BMC Cancer 12(438).
- Contribution to journal › Article
Mark Duration of L-dopa and dopamine agonist monotherapy in Parkinson´s disease
Nissen, T ; Newman, E. J. ; Grosset, K. A. ; Daghem, M ; Pal, G. ; Stewart, M. ; Odin, Per ^LU ; Macphee, G. J. and Gosset, D. G. (2012) In Scottish Medical Journal 57(4). p.217-220
- Contribution to journal › Article
2007
Mark Budesonide in Crohn's disease: Findings of a compassionate-use program
Lyckegaard, E. ; Håkansson, Katarina ^LU and Bengtsson, B. (2007) In Hepato-Gastroenterology 54(79). p.2024-2027
- Contribution to journal › Article
2006
Mark Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration
Tyrrell, Chris J. ; Iversen, Peter ; Tammela, Teuvo ; Anderson, John ; Björk, Thomas ^LU ; Kaisary, Amir V. and Morris, Thomas (2006) In BJU International 98(3). p.563-572
- Contribution to journal › Article

your query:: Remove keywords: tolerability